The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.

Provided herein is a method of monitoring the change of the alpha-4 integrin activities in an individual by correlating with the soluble vascular cell adhesion molecule (sVCAM) and/or soluble mucosal addressin cell adhesion molecule (sMAdCAM) levels. Particularly, this method can be used, for example, to evaluate the pharmacokinetics and pharmacodynamics (PK/PD) of an alpha-4 integrin inhibitor used to treat a disease associated with pathological or chronic inflammation.

An immunochromatography including steps of mixing an antigen-containable specimen and modified magnetic particles, which are magnetic particles modified with a substance having a specific affinity to the antigen; collecting the magnetic particles using magnetism; dissociating the modified magnetic particles to obtain an antigen-concentrated solution by mixing the collected magnetic particles with a dissociation solution, an amount of which is smaller than the antigen-containable specimen; obtaining a neutralized antigen-concentrated solution; spreading gold particle composite bodies on an insoluble carrier having a reaction site at which a second binding substance has been immobilized, in a state where the gold particle composite bodies which are composite bodies of an antigen in the neutralized antigen-concentrated solution and modified gold particles which are gold particles modified with a first binding substance are formed; capturing the gold particle composite bodies at the reaction site; and silver-amplifying the gold particle composite body.

As a technique for specifically detecting cancer cells, provided is a method for detecting cancer cells, including the steps of: bringing BC2LCN lectin into contact with a test sample; and determining the presence or absence or the amount of a sugar chain having a BC2LCN lectin binding activity in the test sample, in which the test sample is a body fluid sample of a test individual.

Provided herein is a method of monitoring the change of the alpha-4 integrin activities in an individual by correlating with the soluble vascular cell adhesion molecule (sVCAM) and/or soluble mucosal addressin cell adhesion molecule (sMAdCAM) levels. Particularly, this method can be used, for example, to evaluate the pharmacokinetics and pharmacodynamics (PK/PD) of an alpha-4 integrin inhibitor used to treat a disease associated with pathological or chronic inflammation.

The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.

The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.

The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.

A mammalian C-type lectin receptor type is identified which is shown to bind IgG antibodies or Fc fragments, thus inducing IVIG-related reversal of inflammation associated with various immune disorders. The identification of a DC-SIGN receptor type which interacts with IgG to promote a biological response reducing inflammation associated with immune disorders provides for methods of screening and selecting compounds which may be useful in treating various immune disorders by acting to modulate a DC-SIGN.sup.(+) cell to signal a second effector macrophage, causing an increase in expression of the FcRIIB receptor and in turn inhibiting a cellular-mediated inflammatory response.

The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.